“…When applied to the cervical spinal cord, it causes bronchodilation, while SCS delivered to the low thoracic and sacral levels causes vasodilatation and increased bladder volume tolerance [33,45,46,62]. Stimulation of the dorsal portion of the spinal cord can also provoke antidromic inhibition of efferent sympathetic activity, leading to a reduction in peripheral vasoconstriction; additionally, it may induce a peripheral release of vasoactive substances such as calcitonin gene-related peptide and nitric oxide, with consequent peripheral vasodilatation [4,12,33,40,41,45,46,51]. Effective therapeutic SCS for neuropathic pain requires the activation of ascending sensory fibers and causes paresthesias covering the painful area, even though the topographical extension of the paresthesias does not always correspond to the expected dermatomes [57].…”